US Patent 9,707,270: Claim Scope, Exclusivity, and Ziconotide Patent Landscape

US Patent No. 9,707,270 protects a treatment protocol that combines continuous intrathecal ziconotide with morphine for severe chronic pain. Its principal limitations are the patient’s existing or concurrent morphine therapy, continuous intrathecal infusion, a defined ziconotide dosing schedule, and, in dependent claims, specific formulation and delivery characteristics. The patent does not broadly cover ziconotide, morphine, or intrathecal analgesia as standalone technologies.

The commercially relevant risk is concentrated in combination use of Prialt or an equivalent ziconotide product with morphine, particularly where the treatment follows the claimed starting dose, titration ceiling, treatment duration, cumulative-dose range, and formulation limitations.

What does US Patent 9,707,270 claim?

The patent has two independent method claims.

Claim	Core protected activity	Key limitations
1	Treating severe chronic pain	Continuous intrathecal ziconotide plus therapeutically effective morphine
11	Treating severe chronic pain	Selecting a patient already receiving morphine, then administering continuous intrathecal ziconotide

Claim 1 requires two therapeutic acts: administering ziconotide and administering morphine. Claim 11 is structured as a patient-selection claim. It targets a patient who is already receiving morphine before ziconotide is administered.

Both independent claims require:

A human patient;
Severe chronic pain;
Continuous intrathecal infusion of ziconotide;
A starting dose of 0.6 micrograms per day;
Titration upward by up to 2.4 micrograms per day per week;
A maximum dose of 7.2 micrograms per day.

The claim language creates a protocol-specific patent rather than a composition-of-matter patent. A competitor that uses ziconotide without morphine, or uses a materially different dosing regimen, would not fall within the literal scope of claims 1 or 11.

How broad are the independent claims?

Claim 1: Concurrent ziconotide and morphine treatment

Claim 1 covers a treatment course in which the patient receives both medicines. It does not expressly require that the drugs be administered in the same syringe, through the same pump, or at the same time.

The morphine can therefore be administered by a separate route, subject to dependent claim 9, which expressly covers systemic administration. The claim does not require systemic morphine in its independent form. Intrathecal, oral, transdermal, or other morphine administration could potentially satisfy the broad “administering ... morphine” language if the treatment otherwise falls within the claim.

The strongest infringement case would involve:

Severe chronic pain;
Continuous intrathecal ziconotide;
A 0.6 microgram-per-day starting dose;
Weekly titration within the stated limit;
A maximum dose no higher than 7.2 micrograms per day; and
Concurrent or coordinated morphine treatment.

Claim 11: Patient-selection strategy

Claim 11 may be commercially important because it focuses on a patient already receiving morphine. The sequence is:

Select a severe-chronic-pain patient receiving therapeutic morphine; and
Add continuous intrathecal ziconotide under the claimed dose schedule.

This claim may apply even if the physician does not initiate morphine as part of the same treatment decision. The claim is directed to escalation or augmentation of an existing morphine regimen.

The distinction between claims 1 and 11 matters in litigation. Claim 1 emphasizes administration of both medicines. Claim 11 emphasizes the pre-existing morphine status of the selected patient. A defendant may challenge whether the claimed treatment steps were performed by one actor, whether the patient’s morphine exposure was therapeutic, or whether the physician used the claimed dosing protocol.

What dependent claims add to the patent scope?

Claims 2 through 10 narrow claim 1. Claims 12 through 20 repeat substantially the same limitations for claim 11.

Claims	Added limitation	Commercial significance
2, 12	Treatment for 14 to 35 days	Targets a defined treatment course
3, 13	Cumulative ziconotide dose of 8.8 to 118.6 micrograms	Creates a course-level dosing limitation
4, 14	Pharmaceutical composition containing an antioxidant	Protects formulation use, not merely treatment
5, 15	Antioxidant is methionine	Narrows formulation coverage
6, 16	Formulation pH of 4 to 4.5	Covers an acidic injectable formulation
7, 17	Single-dose vial	Targets commercial packaging
8, 18	100 micrograms/mL ziconotide concentration	Tracks the marketed concentration
9, 19	Morphine is systemically administered	Covers combination with nonintrathecal morphine
10, 20	Ziconotide delivered through an implantable pump	Targets chronic intrathecal delivery systems

The formulation claims are potentially significant because they align closely with the known pharmaceutical presentation of ziconotide. Prialt is supplied as a sterile solution for intrathecal infusion, with a 100 microgram/mL presentation and methionine-containing formulation characteristics described in FDA labeling. The formulation limitations could therefore be easier to prove against a marketed product than the treatment-duration and cumulative-dose limitations, which depend on patient-specific medical records. (FDA, 2023)

What formulation patents protect ziconotide products?

The patent has a layered formulation position:

Claims 4 and 14 require an antioxidant.
Claims 5 and 15 narrow the antioxidant to methionine.
Claims 6 and 16 require pH between 4 and 4.5.
Claims 7 and 17 require a single-dose vial.
Claims 8 and 18 require a 100 microgram/mL concentration.

These claims do not independently require morphine beyond their dependence on claims 1 or 11. They also do not claim every ziconotide formulation. A formulation using a different antioxidant, a different concentration, a different container, or a pH outside the stated range could avoid literal infringement of the narrower claims.

The most commercially exposed configuration is a 100 microgram/mL single-dose ziconotide vial containing methionine at pH 4 to 4.5, used in a morphine-treated patient through an implantable intrathecal pump. That combination implicates claims 1, 4, 5, 6, 7, 8, and 10, or the corresponding claim set beginning with claim 11.

What dose and treatment duration does the patent require?

The claimed dose schedule is unusually specific:

Parameter	Claimed range or value
Starting dose	0.6 micrograms/day
Weekly upward titration	Up to 2.4 micrograms/day
Maximum daily dose	7.2 micrograms/day
Treatment duration	14 to 35 days in claims 2 and 12
Cumulative dose	8.8 to 118.6 micrograms in claims 3 and 13

The dose limitations create both enforcement opportunities and design-around routes. A physician using a higher starting dose, a different titration interval, or a maximum dose above 7.2 micrograms per day may fall outside the literal scope of the independent claims, depending on the complete treatment record and claim construction.

The FDA-approved Prialt labeling also emphasizes cautious initiation and titration through an intrathecal delivery system, but the approved labeling and the patent claims should not be treated as identical. FDA labeling establishes regulatory directions for use; it does not determine patent infringement. (FDA, 2023)

What is the Orange Book status of US Patent 9,707,270?

The patent’s Orange Book significance depends on whether it is listed against the relevant ziconotide new drug application and whether the listing remains active. Patent listing and patent validity are separate issues.

An Orange Book-listed patent can support a Paragraph IV certification by an abbreviated new drug application applicant. If a brand company receives a proper Paragraph IV notice and sues within the statutory period, FDA approval may be subject to a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions. (FDA, 2024a; 21 U.S.C. § 355)

The claims are method-of-treatment claims. Under Hatch-Waxman, method-of-use patents can be addressed through a Paragraph IV certification or, where applicable, a section viii statement carving out the patented use. The commercial effect depends on the exact Orange Book listing, the approved labeling, and whether the patented combination use is included in the proposed generic label.

A section viii carve-out may reduce direct exposure if the generic label omits the patented morphine-combination use. It does not eliminate all risk where the generic product is marketed for use in the claimed regimen or where induced-infringement theories are available.

When does US Patent 9,707,270 lose exclusivity?

US Patent 9,707,270 issued on July 18, 2017. Its expiration date cannot be calculated from the issue date alone. US utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. (USPTO, 2024)

Event	Date or rule
Patent grant	July 18, 2017
Basic statutory term	Generally 20 years from earliest effective nonprovisional filing
Possible adjustment	Patent-term adjustment may extend the term
Possible terminal disclaimer	May shorten the term to an earlier patent’s expiration
Regulatory exclusivity	Separate from patent term and must be assessed under the FDA exclusivity record

The patent’s remaining enforceability also depends on maintenance-fee payment, post-grant proceedings, reexamination, litigation outcomes, and terminal-disclaimer obligations. A patent can remain listed in the Orange Book while facing validity or enforceability challenges.

Are there Paragraph IV challenges or generic-entry risks?

A generic ziconotide applicant would face several potential pathways:

ANDA pathway

An ANDA applicant could seek approval by demonstrating pharmaceutical equivalence and bioequivalence to the reference product, subject to the product’s dosage form, route, formulation, container, and delivery requirements. Intrathecal administration creates a higher technical and regulatory burden than conventional oral or injectable products.

505(b)(2) pathway

A 505(b)(2) applicant could pursue a modified formulation, dosing regimen, presentation, or delivery system while relying partly on FDA findings for the reference product. This route may be more suitable for a product that differs in concentration, antioxidant, vial configuration, or pump compatibility.

Label carve-out

A generic applicant could attempt to omit the patented morphine-combination indication or other patented method from its labeling. The viability of that approach depends on whether the remaining label has substantial noninfringing uses and whether the patented use is integral to the reference product’s approved labeling.

Litigation theories

Potential disputes would likely involve:

Whether the patient had “severe chronic pain”;
Whether morphine was administered at a therapeutically effective amount;
Whether ziconotide was delivered by continuous intrathecal infusion;
Whether the starting dose and titration schedule matched the claims;
Whether the patient remained within the 14-to-35-day treatment window;
Whether the cumulative dose fell within the claimed range;
Whether a formulation contained methionine at the claimed pH;
Whether the product was supplied in a single-dose 100 microgram/mL vial; and
Whether an implantable pump was used.

Claims 1 and 11 are method claims, so physician and provider conduct is more important than ordinary product-by-product patent analysis. Generic manufacturers also face induced-infringement exposure if their labeling, promotional materials, training, or distribution practices encourage the patented regimen.

How strong is the patent estate for ziconotide?

US Patent 9,707,270 is strongest as a targeted combination-treatment patent. Its strengths are:

Two independent claims with different factual structures;
A specific and commercially recognizable ziconotide dosing protocol;
Coverage of patients already receiving morphine;
Dependent claims directed to the likely marketed formulation;
Implantable-pump coverage;
Course-level treatment and cumulative-dose limitations.

Its weaknesses are equally specific:

It does not broadly claim ziconotide itself;
It does not broadly claim morphine-ziconotide coadministration without the specified infusion regimen;
Several limitations depend on patient records;
Dose deviations may avoid literal infringement;
Formulation claims may be designed around through concentration, antioxidant, pH, or packaging changes;
Method claims may face divided-infringement and induced-infringement disputes;
The claims may be vulnerable to anticipation or obviousness arguments based on prior clinical use of ziconotide, morphine, intrathecal pumps, and combination analgesia.

The patent’s commercial strength is therefore highest against a product or provider that follows the claimed Prialt-like presentation and dosing regimen. It is weaker against alternative regimens, non-methionine formulations, different concentrations, or products marketed without the morphine-combination use.

How does ziconotide patent protection compare with generic and biosimilar risk?

Ziconotide is a synthetic peptide drug, not a reference biologic ordinarily analyzed through the BPCIA biosimilar framework. The primary competitive pathway is therefore small-molecule drug approval through an ANDA or, for modified products, a 505(b)(2) application. FDA’s Purple Book biosimilar pathway is not the central route for a ziconotide competitor. (FDA, 2024b)

The main barriers are technical rather than purely patent-based:

Sterile manufacture of a peptide drug;
Control of aggregation and oxidation;
Stability in an acidic formulation;
Compatibility with intrathecal pumps;
Low-volume dosing accuracy;
Container and closure integrity;
Intrathecal safety;
Demonstration of pharmaceutical equivalence and bioequivalence.

A competitor that reproduces the 100 microgram/mL methionine-containing single-dose formulation may face greater patent exposure than one that develops a different presentation. A different formulation may reduce claim risk but increase FDA development and comparability burdens.

What generic launch scenarios exist?

Scenario	Patent exposure	Likely commercial result
Same 100 microgram/mL formulation and same dosing regimen	High	Paragraph IV litigation risk
Same product with morphine-combination labeling	High	Direct method-of-use exposure
Product with section viii carve-out	Reduced but not eliminated	Potential approval without patented use
Different concentration or antioxidant	Lower for dependent formulation claims	Higher formulation-development burden
Different titration regimen	Lower literal infringement risk	Clinical and labeling differences
505(b)(2) intrathecal formulation	Fact-specific	Potential patent and regulatory litigation
Off-label physician use after approval	Provider and inducement exposure	Depends on label and promotional conduct

What is the litigation and licensing landscape?

The supplied claim set does not establish a current infringement action, settlement, license, or covenant not to sue. Patent litigation and licensing cannot be inferred from the existence of the patent or from FDA approval alone.

A complete freedom-to-operate review should treat US Patent 9,707,270 as one layer in a broader estate that may include:

Ziconotide composition patents;
Peptide synthesis and purification patents;
Intrathecal delivery and pump patents;
Stabilized formulation patents;
Method-of-use patents;
Orange Book-listed patents for the reference product;
Patents held by the product owner, licensees, or prior commercial rights holders.

The most material licensing question is whether the patent owner has granted rights for commercial use of the patented morphine-combination regimen, the formulation, or both. A product license does not necessarily grant freedom to practice unrelated pump, manufacturing, or formulation patents.

Key Takeaways

US Patent 9,707,270 is a method-of-treatment patent focused on ziconotide plus morphine for severe chronic pain.
Claims 1 and 11 are the principal claims; claim 1 covers administration of both drugs, while claim 11 focuses on selecting a patient already receiving morphine.
The claimed ziconotide regimen starts at 0.6 micrograms per day, permits titration of up to 2.4 micrograms per day per week, and caps the dose at 7.2 micrograms per day.
Dependent claims cover 14-to-35-day treatment, cumulative dosing, methionine, pH 4 to 4.5, a single-dose vial, 100 micrograms/mL concentration, systemic morphine, and implantable pumps.
The patent does not broadly block all ziconotide products or all intrathecal pain treatment.
Generic risk is highest for a Prialt-like product used with morphine under the claimed regimen.
Design-around options include changing the dosing protocol, formulation, concentration, antioxidant, packaging, or patented use in labeling.
The patent’s exact expiration and current Orange Book status require review of the USPTO and FDA records, including terminal disclaimers, maintenance status, patent-term adjustment, and any listing changes.

FAQs

Can a physician infringe US Patent 9,707,270 by using ziconotide off label?

Yes, potentially. Off-label use does not provide a patent exemption. Liability would depend on whether the physician’s conduct satisfies every limitation of an asserted method claim.

Does the patent cover ziconotide used alone?

No. The independent claims require morphine treatment or selection of a patient receiving morphine. Ziconotide monotherapy is outside the literal scope of the independent claims as provided.

Does systemic morphine fall within the patent?

Yes. Claims 9 and 19 expressly cover systemic morphine administration. The independent claims are broader because they do not limit morphine to a particular route.

Can a competitor avoid the patent by using a different ziconotide concentration?

A different concentration may avoid claims 8 and 18, but it would not automatically avoid claims 1 and 11. The competitor would still need to assess the dose schedule, morphine treatment, continuous intrathecal infusion, and other claim limitations.

Does the patent create biosimilar exclusivity for ziconotide?

No. Ziconotide is generally analyzed as a drug product under the ANDA or 505(b)(2) frameworks, not as a conventional BPCIA biosimilar product. Patent and regulatory barriers remain relevant under those pathways.

References

Food and Drug Administration. (2023). Prialt (ziconotide acetate) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,707,270: Methods for treating severe chronic pain.
United States Patent and Trademark Office. (2024). Patent term calculator and patent term adjustment guidance. U.S. Department of Commerce.
21 U.S.C. § 355. New drugs and antibiotics.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2540895	⤷ Start Trial
Canada	2930900	⤷ Start Trial
European Patent Office	1689401	⤷ Start Trial
Japan	2007507538	⤷ Start Trial
Japan	2011173931	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,707,270

Summary for Patent: 9,707,270